Resistance to BRAFV600E inhibitors often occurs in melanoma patients. Here, the authors describe a potential mechanism of acquired drug resistance mediated by tumor-associated B cells-derived IGF-1.
- Rajasekharan Somasundaram
- Gao Zhang
- Stephan N. Wagner